ClinicalTrials.gg
CompletedNCT06785675Updated Nov 12, 2026

Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.

An observational study in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Completed at 4 sites in United Arab Emirates. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

Updated Nov 12, 2026Now CompletedStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
63
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.

Enrollment
9th of 10
63 · median 125
Started
2025
with 6 others
Observational
10 of 21
6 open now
Registered
10th of 21
by date

Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 9th largest by enrollment of the 10 observational ones that give a count, is one of 7 that started in 2025, is one of 10 observational ones, and was the 10th registered.

Hidradenitis Suppurativa

286 studies on the registry are indexed under Hidradenitis Suppurativa; 89 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 63 Hidradenitis Suppurativa studies recruiting now, 35 (56%) set no upper age limit and 17 (27%) stop at 75 or younger; 13 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hidradenitis Suppurativa by Novartis, or all of them as a file.
02

Study summary

This study will be conducted to address the lack of concrete data on the impact of pharmaceutical intervention on short-term patient satisfaction and quality of life (QoL) in patients with Hidradenitis Suppurativa (HS) in real-world settings, especially in the Gulf Region.

Read the detailed description

This is a 24-week longitudinal single-arm prospective study based on data collected from EMRs along with patient-reported outcomes questionnaires (TSQM and DLQI) to evaluate patient-reported satisfaction and early quality of life experiences among HS patients who are newly initiated on Secukinumab. We will be using questionnaires at baseline and at week 24 to report on pre-defined outcomes in a representative HS population across the United Arab Emirates. The data will be collected using an electronic Case Report Form (eCRF) from both data sources (Electronic Medical Report and Questionnaires).

03

Conditions studied

  • Hidradenitis Suppurativa
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Hidradenitis Suppurativa who are newly initiated on Secukinumab, across the United Arab Emirates.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with a confirmed diagnosis of active moderate to severe HS (Hurley Score 2-3)
  • Male or Female adult patients ≥ 18 years of age at the time of data collection
  • Patient newly initiated on Secukinumab (first dose to coincide within 1 month of the signature of the )
  • Patients with a diagnosis of HS who are currently using antibiotics/ have undergone surgery or not as part of their routine clinical management are eligible for inclusion.
  • Patients with a diagnosis of HS who have a history of previous treatment with Adalimumab or any other anti-TNF agent as part of their routine clinical management or biologic naïve are eligible for inclusion.
  • Agreed to sign an informed consent to be able to fill in the questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Patients not fulfilling any of the abovementioned inclusion criteria.
  • Patient's refusal to be included in the study or refusal to sign the .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
63 participants (actual)
Patient registry
No

Groups and cohorts

  • Secukinumab

    Patients who are newly initiated on treatment with Secukinumab

    Other: Secukinumab

Interventions

  • OtherSecukinumab

    This is an observational study. There is no treatment allocation.

06

What researchers measure

Primary outcomes

  1. The absolute scores of each of the 4 domains of the Treatment Satisfaction Questionnaire for Medication (TSQM) questionnaire

    TSQM scoring is calculated by domain, and each domain score is computed by summing the individual TSQM items in each domain and then transforming the composite score into a value ranging from 0 to 100, with higher scores indicating higher patient satisfaction. 4 Domains: Effectiveness Side Effects Convenience Global Satisfaction

    Time frame: At Week 24

Secondary outcomes

  1. Change from baseline of the Dermatology Life Quality Index (DLQI) Questionnaire

    DLQI is a questionnaire designed to measure the impact of skin conditions on a patient's health-related quality of life. It contains 10 simple, self-administered questions. Focuses on the past week's experiences related to the skin condition. Each question uses a 4-point Likert scale: "Not at all," "A little," "A lot," "Very much."

    Time frame: Baseline, Week 24

  2. Change from baseline in the Numerical Rating Scale (NRS)

    The NRS is commonly used for measuring pain intensity and is well validated. It is scored from 0-10 (0 meaning no pain and 10 meaning the worst pain imaginable).

    Time frame: Baseline, Week 24

  3. Age (years)

    Characteristics of Hidradenitis Suppurativa (HS) patients started on Secukinumab

    Time frame: Baseline

  4. Gender (male/female)

    Characteristics of HS patients started on Secukinumab

    Time frame: Baseline

  5. Ethnicity

    Characteristics of HS patients started on Secukinumab

    Time frame: Baseline

  6. Weight (kilogram)

    Characteristics of HS patients started on Secukinumab

    Time frame: Baseline

  7. Height (meters)

    Characteristics of HS patients started on Secukinumab

    Time frame: Baseline

  8. Socio-economic status

    Characteristics of HS patients started on Secukinumab

    Time frame: Baseline

  9. Smoking status

    Characteristics of HS patients started on Secukinumab

    Time frame: Baseline

  10. Duration of the disease (time since diagnosis)

    Characteristics of HS patients started on Secukinumab

    Time frame: Baseline

  11. Previous HS-related treatment

    Characteristics of HS patients started on Secukinumab

    Time frame: Baseline

  12. Time since diagnosis to start of the first treatment, and from time since diagnosis to start of Secukinumab

    Characteristics of HS patients started on Secukinumab

    Time frame: Baseline

  13. Hurley Stage

    Characteristics of HS patients started on Secukinumab

    Time frame: Baseline

  14. Number of inflammatory nodules, number of abscesses, and fistulas

    Characteristics of HS patients started on Secukinumab

    Time frame: Baseline

  15. Previous HS-related surgeries

    Characteristics of HS patients started on Secukinumab

    Time frame: Baseline

  16. Previous use of biologic treatment

    Characteristics of HS patients started on Secukinumab

    Time frame: Baseline

  17. Previous and current use of antibiotics treatment

    Characteristics of HS patients started on Secukinumab

    Time frame: Baseline

07

Study locations

4 sites
  • Novartis Investigative Site
    Abu Dhabi, United Arab Emirates
  • Novartis Investigative Site
    Al Ain Abu Dhabi, United Arab Emirates
  • Novartis Investigative Site
    Ras al-Khaimah, United Arab Emirates
  • Novartis Investigative Site
    Sharjah city, United Arab Emirates
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Jul 2026, 14 months.

Of 46 observational studies under Hidradenitis Suppurativa, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 25. This study's 14 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Mar 2025 → Apr 2025, primary completion Oct 2026 → Jul 2026 and completion Oct 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Jan 21, 2025
StartActual
Apr 28, 2025was Mar 2025
Primary completionActual
Jul 16, 2026was Oct 2026
CompletionActual
Jul 16, 2026was Oct 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 12, 2026
Sites
1 site added, 1 site removed
Show site
  • Novartis Investigative Site · Al Ain Abu Dhabi, United Arab Emirates
Show 1 removed
  • Novartis Investigative Site · Al Ain Abu Dhabi, United Arab Emirates
Nov 12, 2026
Start date
Mar 10, 2025→Apr 28, 2025
Nov 12, 2026
Primary completion
Oct 10, 2026→Jul 16, 2026 (actual)
Nov 12, 2026
Study completion
Oct 10, 2026→Jul 16, 2026 (actual)
Nov 12, 2026
Enrollment
53→63
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Active, not recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Novartis Investigative Site · Al Ain Abu Dhabi, United Arab Emirates
    Show 1 removed
    • Novartis Investigative Site · Al Ain Abu Dhabi, United Arab Emirates
    Start date Mar 10, 2025→Apr 28, 2025
    Primary completion Oct 10, 2026→Jul 16, 2026 (now actual)
    Study completion Oct 10, 2026→Jul 16, 2026 (now actual)
    Enrollment 53→63
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06785675
Responsible party
Sponsor
First posted
Jan 21, 2025
Start date
Apr 28, 2025
Primary completion
Jul 16, 2026
Completion
Jul 16, 2026
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion